The price of Ivosidenib is affected by factors such as dosage, region, and medical insurance policies. In China, the price per box typically ranges from tens of thousands of yuan. Specific prices should be confirmed with hospitals or authorized pharmacies. This is a prescription drug; strict adherence to doctor's instructions and a thorough evaluation of the treatment plan are necessary before use.
Price Influencing Factors
Dosage and Dosage: Different dosages (e.g., 250mg x 60 tablets/box) have significant price differences, and the required dosage for the entire treatment course will also affect the total cost.
Medical Insurance Policies: Ivosidenib is included in some local medical insurance or specific disease reimbursement lists. Out-of-pocket expenses may be reduced by 50%-70% after medical insurance coverage, but this requires meeting the indications (e.g., specific IDH1 mutant leukemia) and other conditions.
Purchase Channels: Prices may vary between hospitals, designated pharmacies, and approved online platforms. Purchase through official channels to avoid the risks associated with unauthorized channels.
Other Precautions
Indication Restrictions: Evonib is primarily used for relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. Eligibility must be confirmed through genetic testing.
Generic Drugs and Clinical Trials: Currently, there are no generic versions available in China. However, patients can focus on clinical trials conducted by reputable medical institutions. Eligible patients may receive free treatment.
Patient Assistance Programs: Some pharmaceutical companies or charitable organizations offer medication subsidies or installment payment plans. Consult your attending physician or hospital social work department for details.
Medical Guidance and Recommendations
Strictly Follow Doctor's Orders: Dosage needs to be adjusted according to individual conditions. Regular monitoring of blood routine tests, liver and kidney function, and gene mutation status is necessary during treatment.
Side Effect Management: Common adverse reactions include fatigue and joint pain. Immediate medical attention is required if QT interval prolongation or differentiation syndrome occurs.
Multidisciplinary Treatment: It is recommended to develop a comprehensive treatment plan under the guidance of hematologists and oncologists, in conjunction with chemotherapy and transplantation.
For further information on costs or eligibility, it is recommended to consult a hematologist at a tertiary hospital with your medical records.
